Aurora Cannabis Launches New CBD Lozenge in Canada, Developed With Vectura Fertin Pharma
Aurora Cannabis Launches New CBD Lozenge in Canada, Developed With Vectura Fertin Pharma
Aurora Cannabis Inc. ("Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce the launch of the newly developed Luo CBD lozenge.
大麻股公司Aurora Cannabis Inc.（「Aurora」）（納斯達克：ACB）（tsx：ACB）與創新健康保健公司Vectura Fertin Pharma, Inc.（"Vectura Fertin Pharma"）非常高興地宣佈新開發的Luo CBD含片的推出。
The high-quality CBD lozenge was developed by Vectura Fertin Pharma and adheres to stringent safety, quality and regulatory standards to address unmet medical and health needs. It is the first of Vectura Fertin Pharma's medical cannabis products to launch in Canada. The CBD lozenge is being manufactured, packaged and labelled by Cogent, a Vectura Fertin Pharma subsidiary, for sale and will be distributed by Aurora through its leading direct-to-patient e-commerce platform. The CBD lozenge, which has a novel dissolvable format and is easy to dose, is now available for patients on Aurora's Canadian medical cannabis patient platform as authorised by healthcare professionals.
高品質的CBD含片是由Vectura Fertin Pharma開發的，嚴格遵守安全、質量和監管標準，以滿足未滿足的醫療和健康需求。這是Vectura Fertin Pharma在加拿大推出的首款醫療大麻產品。Vectura Fertin Pharma的子公司Cogent負責製造、包裝和貼標銷售，並通過Aurora的領先患者電子商務平台進行分銷。這款含片具有新穎可溶解的格式，易於計量，現在已經在Aurora的加拿大醫療大麻患者平台上推出，並得到了醫療專業人士的授權使用。
譯文內容由第三人軟體翻譯。